ANTIHYPERTENSIVE MEDICATION-TAKING - INVESTIGATION OF A SIMPLE REGIMEN

被引：56

作者：

GUERRERO, D ^{[1
]}

RUDD, P ^{[1
]}

BRYANTKOSLING, C ^{[1
]}

MIDDLETON, BF ^{[1
]}

机构：

[1] STANFORD UNIV,MED CTR,SCH MED,STANFORD,CA 94305

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1993年 / 6卷 / 07期

关键词：

COMPLIANCE; HYPERTENSION; DRUG THERAPY; ISRADIPINE; CLINICAL TRIAL; ELECTRONIC MONITORING;

D O I：

10.1093/ajh/6.7.586

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

In search of strategies to improve compliance, we assessed medication-taking behavior among 19 ambulatory hypertensives, using both pill counts and electronic monitoring. The regimen consisted of one pill each day for less-than-or-equal-to 63 weeks with return visits at 1 to 4 week intervals. The study population was 79% male, 68% white, and 16% black with mean (+/- SEM) age 58.4 +/- 2.5 years. Only 51% of the intervisit intervals displayed greater-than-or-equal-to 80% of vial openings within the desirable range (24 +/- 6 h). Pill counts detected only 2% of suboptimal interdosing intervals identified by electronic monitoring. Early changes in compliance correlated well with later changes (r = 0.83, P = .002). A few of the subjects exhibited a large deviation from the prescription, uncorrectable with drugs having a long duration of action. We conclude that (a) pill counts tend to overestimate patients' compliance rates, (b) changes in medication-taking behavior early in therapy may predict subsequent compliance rates; and (c) prolonging drug action may compensate for some imperfect medication-taking behavior.

引用

页码：586 / 592

页数：7

共 22 条

[1] Cramer J.A., Mattson R.H., Prevey M.L., Et al., How often is medication taken as prescribed? A novel assessment technique, JAMA, 261, pp. 3273-3277, (1989)
[2] Eisen S.A., Miller D.K., Woodward R.S., Et al., The effect of prescribed daily dose frequency on patient medication compliance, Arch Intern Med, 150, pp. 1881-1884, (1990)
[3] Rudd P., Ahmed S., Zachary V., Et al., Improved compliance measures: Applications in an ambulatory hypertensive drug trial, Clin Pharmacol Ther, 48, pp. 676-685, (1990)
[4] Joyce C., Patient co-operation and the sensitivity of clinical trials, J Chron Dis, 15, pp. 1025-1036, (1962)
[5] Pullar T., Kumar S., Tindall H., Feely M., Time to stop counting the tablets?, Clin Pharmacol Ther, 46, pp. 163-168, (1989)
[6] Lancet, 337, pp. 823-824, (1991)
[7] Stewart M., The validity of an interview to assess a patient’s drug taking, Am J Prev Med, 3, pp. 95-100, (1987)
[8] Rudd P., Byyny R.L., Zachary V., Et al., The natural history of medication compliance in a drug trial: Limitations of pill counts, Clin Pharmacol Ther, 46, pp. 169-176, (1989)
[9] Mazer N., Abisch E., Gfeller J.C., Et al., Intragastric behavior and absorption kinetics of a normal and "floating" mod- ified-release capsule of isradipine under fasted and fed conditions, J Pharm Sci, 77, pp. 647-657, (1988)
[10] Christensen H.R., Kampmann J.P., Simonsen K., A randomized comparison of isradipine slow release given once daily with isradipine twice daily on 24 hour blood pressure in hypertensive patients, J Hum Hypertens, 5, pp. 121-127, (1991)

← 1 2 3 →